Automera, a Singapore-based biotechnology company that focuses on the development of autophagy-targeting chimera small molecules (AUTACs), raised $16M in Series A funding.
The round was led by Accelerator Life Science Partners (ALSP) and ClavystBio, with participation from EDBI, Xora Innovation, and other undisclosed investors. Joining the Board of Directors are Loong Wang, from Automera, Dr. Alice Chen and Thong Q. Le, from ALSP, and Dr. Wen Qi Ho, from ClavystBio.
The company intends to use the funds to expand its development efforts.
Founded by Michael Lazarou, Loong Wang, and Taiyang Zhang, Automera is an early-stage company focused on the development of a novel therapeutic approach via autophagy-based targeted protein degradation. It aims to leverage its understanding of autophagy, drug development capabilities, and access to quantum chemistry and generative AI-enabled insights to enhance its drug development programs. Automera’s AUTAC platform has broad potential across cancer and other disease areas, with oncology being the initial lead program.
Automera has assembled a distinguished scientific advisory group that includes Associate Professor Michael Lazarou, Automera’s Scientific Co-Founder at the Walter and Eliza Hall Institute of Medical Research (WEHI) and the Monash Biomedicine Discovery Institute, Dr. Nicholas Ktistakis from Babraham Institute, Dr. Gene Yeo from the University of California San Diego (UCSD) and Dr. Kendall Mohler from ALSP.
FinSMEs
27/09/2023